- Home
- LFCR vs ALDX Comparison
LFCR vs ALDX Comparison
Compare LFCR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- ALDX
- Stock Information
- Founded
- LFCR 1986
- ALDX 2004
- Country
- LFCR United States
- ALDX United States
- Employees
- LFCR N/A
- ALDX N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- LFCR Health Care
- ALDX Health Care
- Exchange
- LFCR Nasdaq
- ALDX Nasdaq
- Market Cap
- LFCR 308.8M
- ALDX 270.7M
- IPO Year
- LFCR N/A
- ALDX 2014
- Fundamental
- Price
- LFCR $7.50
- ALDX $5.48
- Analyst Decision
- LFCR Buy
- ALDX Strong Buy
- Analyst Count
- LFCR 4
- ALDX 2
- Target Price
- LFCR $8.00
- ALDX $9.50
- AVG Volume (30 Days)
- LFCR 224.3K
- ALDX 1.3M
- Earning Date
- LFCR 08-25-2025
- ALDX 07-31-2025
- Dividend Yield
- LFCR N/A
- ALDX N/A
- EPS Growth
- LFCR N/A
- ALDX N/A
- EPS
- LFCR N/A
- ALDX N/A
- Revenue
- LFCR $130,309,000.00
- ALDX N/A
- Revenue This Year
- LFCR $1.64
- ALDX N/A
- Revenue Next Year
- LFCR $2.91
- ALDX N/A
- P/E Ratio
- LFCR N/A
- ALDX N/A
- Revenue Growth
- LFCR 7.23
- ALDX N/A
- 52 Week Low
- LFCR $3.68
- ALDX $1.14
- 52 Week High
- LFCR $8.85
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- LFCR 45.04
- ALDX 79.28
- Support Level
- LFCR $7.39
- ALDX $4.88
- Resistance Level
- LFCR $7.67
- ALDX $5.66
- Average True Range (ATR)
- LFCR 0.35
- ALDX 0.33
- MACD
- LFCR -0.13
- ALDX 0.05
- Stochastic Oscillator
- LFCR 4.79
- ALDX 82.80
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.